United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioNTech SE

The pharmaceutical heavyweight thinks it won't need any more help to whip up new mRNA-based vaccines.

Pfizer to Develop mRNA Vaccines Without BioNTech

Pfizer Inc (NYSE: PFE) has started an early-stage U.S. trial of an oral COVID-19 antiviral therapy, dubbed as PF-07321332. The drugmaker, which developed the first authorized COVID-19 vaccine in the U.S. with Germany's BioNTech SE (NASDAQ: BNTX), said the antiviral candidate showed potent activity against SARS-CoV-2 in lab studies.

Pfizer Starts Early-Stage Study Of Oral Antiviral COVID-19 Drug

Shares of Pfizer Inc. were down 1.1% in trading on Tuesday after the drug maker said it initiated a Phase 1 clinical trial testing its experimental oral antiviral as a COVID-19 treatment. The early-stage study, which is being conducted in the U.S., will evaluate the safety and tolerability of the drug.

Pfizer starts early-stage study of oral COVID-19 treatment

After bringing the first vaccine to market, Pfizer hopes for next breakthrough.

Pfizer Testing Oral Covid Treatment — Would Be First To Market

Pfizer Inc's (NYSE: PFE) chief executive Albert Bourla said that the company now aims to expand its vaccine business by developing new shots using the mRNA technology to target other viruses and pathogens beyond the coronavirus, reports the Wall Street Journal. The mRNA technology was used in working on the COVID-19 vaccine with its German partner BioNTech SE (NASDAQ: BNTX).

Pfizer Plans To Develop New mRNA-Based Vaccines By Itself, Says CEO: WSJ

Philip Morris

Pfizer and Philip Morris offer excellent bang for your buck.

2 Dirt-Cheap Value Stocks to Buy Right Now

Bristol-Myers

Merck

A look at undervalued pharma stocks offering yields that are at least double that of the S&P 500

3 Undervalued Pharma Stocks for Sleep-Well-at-Night Income

The drug is part of a class of medicines called protease inhibitors and works by inhibiting an enzyme that the virus needs to replicate in human cells.

Pfizer begins early stage clinical trial testing oral antiviral drug for Covid

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that it is progressing to multiple ascending doses after completing the dosing of single ascending doses in a Phase 1 study in healthy adults to evaluate the safety and tolerability of an investigational, novel oral antiviral therapeutic for SARS-CoV-2, the virus that causes COVID-19. This Phase 1 trial is being conducted in the United States. The oral antiviral clinical candidate PF-07321332, a SARS-CoV2-3CL protease inhibitor,

Pfizer Initiates Phase 1 Study of Novel Oral Antiviral Therapeutic Agent Against SARS-CoV-2

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, May 4, 2021. The purpose of the call is to provide an update on Pfizer's results, as reflected in the company's First Quarter 2021 Performance Report, to be issued that morning. To view and listen to the webcast and view the Performance Report, visit our web site at www.pfizer.com/investors. Informati

Pfizer Invites Public to View and Listen to Webcast of Pfizer May 4 Conference Call with Analysts

While Pfizer has a Covid-19 vaccine out for the public, PFE stock isn't getting much love from Wall Street. Let's avoid it for now.

Why You Should Avoid Pfizer Stock Despite Its Covid-19 Vaccine

The FDA no longer requires PFE to transport vaccines at ultra-low temperatures.

Pfizer: Ultra-Cold Storage Of COVID-19 Vaccine No Longer Required

Just how many billions, though, remains to be seen.

These 15 Words From Pfizer's CFO Could Translate to Billions in Sales for Its COVID Vaccine

Pfizer stock is good value here given its valuation history. PFE stock is worth at least 18% more based on its historical yield and forward P/E ratio.

Pfizer Stock Is a Good Value Given Its Valuation History

Eli Lilly

Ahead of an advisory committee meeting scheduled for later this week, the FDA released its in-depth review of Pfizer Inc (NYSE: PFE) and Eli Lilly And Co's (NYSE: LLY) tanezumab, an anti-NGF osteoarthritis drug. What Happened: Potential FDA approval for tanezumab still looked rocky as the regulator casts doubt over its safety.

Pfizer/Eli Lilly's Tanezumab Safety Profile Fails To Impress FDA Even After 15 Years Of Development Across 41 Trials

PFE stock is worth a shot because shares of Pfizer are fairly priced and the company offers growth and a solid dividend. The post 3 Reasons Pfizer Stock Is Worth a Shot appeared first on InvestorPlace.

3 Reasons Pfizer Stock Is Worth a Shot

Johnson & Johnson

Moderna

Many people have rushed to invest in vaccine markers. Here's why this Fool didn't.

Why I Didn't Jump on the Coronavirus Vaccine Stock Bandwagon

Biogen

Regeneron Pharmaceuticals

They're making headway into tomorrow's hot markets.

Got $5,000? Consider These 3 Leading Pharma Stocks

AstraZeneca

Novavax

Some stocks could be big winners and losers depending on what the answer to this question is.

The Multibillion-Dollar Question: How Long Do COVID Vaccines Last?

BioCryst Pharmaceuticals

Marker Therapeutics Inc

Pacira Pharmaceuticals

ProQR Therapeutics

Rubius Therapeutics Inc

Zealand Pharma

Biotech stocks reversed course in the week ended March 19 amid mixed news flow on data readouts and lackluster broader market performance. Rubius Therapeutics, Inc. (NASDAQ: RUBY) was among the biggest gainers of the week after the biopharma reported positive Phase 1/2 data for its RTX-240 in solid tumors.

FDA Decisions For Pfizer, Eli Lilly And Bluebird Bio, Bristol-Meyers Squibb, Plus New Data And Earnings

Brookfield Property REIT

Gladstone Investment

B. Riley Financial

Shell Midstream Partners LP

AT&T

American Tower

Dividend stocks remain one of the most stable segments to pour your capital into. Here are seven companies will put your mind at ease.

7 Dividend Stocks You Can Trust Your Retirement To

AstraZeneca's Covid-19 vaccine was seen as key to fighting the pandemic globally, given its low cost and easy distribution, but its roll-out and uptake haven't exactly been smooth. The shot was recently suspended from use in multiple countries including Germany, Denmark, Norway, and France due.

Will AstraZeneca's Covid-19 Troubles Help Pfizer Stock?

Pyxis Oncology has entered into a worldwide license agreement with Pfizer Inc (NYSE: PFE) to develop and commercialize two antibody-drug conjugates (ADC) for oncology indications. Under the terms of the agreement, Pyxis has a global license to develop and commercialize two candidates, PYX-201 and PYX-203.

Pfizer Out-Licenses Two ADC Candidates In Cancer Settings To Pyxis Oncology

Some vaccine makers are better positioned than others.

Which COVID Stocks Are the Best Picks if Coronavirus Variants Spread?

AmerisourceBergen

The current valuation suggests that investors purchasing the index today could suffer through negative returns for the next 2 to 3 years or longer. Low interest rates have generated strong demand for dividend growth stocks.

News for Pfizer Stock (PFE)